Is the Options Market Predicting a Spike in RedHill Biopharma (RDHL) Stock?Zacks Investment Research • 12/28/20
RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19PRNewsWire • 11/25/20
RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM DiseasePRNewsWire • 11/20/20
RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 DiseasePRNewsWire • 11/17/20
RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming WeeksPRNewsWire • 11/16/20
RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/12/20
RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription GrowthGlobeNewsWire • 11/12/20
RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 CombinationGlobeNewsWire • 11/04/20
RedHill Biopharma Presents New Data from Talicia®'s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori EradicationGlobeNewsWire • 10/26/20
RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM InfectionsGlobeNewsWire • 10/14/20
RedHill Biopharma Announces Partnerships to Expand Manufacturing for COVID-19 Therapeutic Candidate OpaganibGlobeNewsWire • 10/13/20
RedHill Biopharma’s Opaganib COVID-19 Study Passes Second Independent Committee ReviewGlobeNewsWire • 10/07/20
RedHill Biopharma to Present at BIO Investor and BIO-Europe 2020 Virtual ConferencesGlobeNewsWire • 10/06/20